ResMed Statistics
Total Valuation
ResMed has a market cap or net worth of $27.03 billion. The enterprise value is $28.21 billion.
| Market Cap | 27.03B |
| Enterprise Value | 28.21B |
Important Dates
The next confirmed earnings date is Thursday, April 25, 2024, after market close.
| Earnings Date | Apr 25, 2024 |
| Ex-Dividend Date | Feb 7, 2024 |
Share Statistics
ResMed has 147.09 million shares outstanding. The number of shares has increased by 0.09% in one year.
| Shares Outstanding | 147.09M |
| Shares Change (YoY) | +0.09% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 0.82% |
| Owned by Institutions (%) | 57.23% |
| Float | 145.65M |
Valuation Ratios
The trailing PE ratio is 30.38 and the forward PE ratio is 23.24. ResMed's PEG ratio is 1.75.
| PE Ratio | 30.38 |
| Forward PE | 23.24 |
| PS Ratio | 6.00 |
| Forward PS | 5.68 |
| PB Ratio | 6.03 |
| P/FCF Ratio | 28.09 |
| PEG Ratio | 1.75 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.57, with an EV/FCF ratio of 29.31.
| EV / Earnings | 31.69 |
| EV / Sales | 6.26 |
| EV / EBITDA | 20.57 |
| EV / EBIT | 24.40 |
| EV / FCF | 29.31 |
Financial Position
The company has a current ratio of 3.11, with a Debt / Equity ratio of 0.31.
| Current Ratio | 3.11 |
| Quick Ratio | 1.23 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | 1.01 |
| Debt / FCF | 1.45 |
| Interest Coverage | 19.71 |
Financial Efficiency
Return on equity (ROE) is 21.20% and return on invested capital (ROIC) is 15.74%.
| Return on Equity (ROE) | 21.20% |
| Return on Assets (ROA) | 13.10% |
| Return on Capital (ROIC) | 15.74% |
| Revenue Per Employee | $444,189 |
| Profits Per Employee | $87,809 |
| Employee Count | 10,140 |
| Asset Turnover | 0.67 |
| Inventory Turnover | 2.10 |
Taxes
In the past 12 months, ResMed has paid $207.44 million in taxes.
| Income Tax | 207.44M |
| Effective Tax Rate | 18.90% |
Stock Price Statistics
The stock price has decreased by -19.92% in the last 52 weeks. The beta is 0.67, so ResMed's price volatility has been lower than the market average.
| Beta (1Y) | 0.67 |
| 52-Week Price Change | -19.92% |
| 50-Day Moving Average | 185.92 |
| 200-Day Moving Average | 172.51 |
| Relative Strength Index (RSI) | 47.67 |
| Average Volume (30 Days) | 1,062,117 |
Short Selling Information
The latest short interest is 7.89 million, so 5.37% of the outstanding shares have been sold short.
| Short Interest | 7.89M |
| Short Previous Month | 6.76M |
| Short % of Shares Out | 5.37% |
| Short % of Float | 5.42% |
| Short Ratio (days to cover) | 6.91 |
Income Statement
In the last 12 months, ResMed had revenue of $4.50 billion and earned $890.39 million in profits. Earnings per share was $6.05.
| Revenue | 4.50B |
| Gross Profit | 2.48B |
| Operating Income | 1.14B |
| Pretax Income | 1.10B |
| Net Income | 890.39M |
| EBITDA | 1.37B |
| EBIT | 1.16B |
| Earnings Per Share (EPS) | $6.05 |
Balance Sheet
The company has $210.25 million in cash and $1.39 billion in debt, giving a net cash position of -$1.18 billion or -$8.03 per share.
| Cash & Cash Equivalents | 210.25M |
| Total Debt | 1.39B |
| Net Cash | -1.18B |
| Net Cash Per Share | -$8.03 |
| Equity / Book Value | 4.48B |
| Book Value Per Share | 30.47 |
| Working Capital | 1.61B |
Cash Flow
In the last 12 months, operating cash flow was $1.08 billion and capital expenditures -$116.65 million, giving a free cash flow of $962.46 million.
| Operating Cash Flow | 1.08B |
| Capital Expenditures | -116.65M |
| Free Cash Flow | 962.46M |
| FCF Per Share | $6.54 |
Margins
Gross margin is 55.11%, with operating and profit margins of 25.31% and 19.77%.
| Gross Margin | 55.11% |
| Operating Margin | 25.31% |
| Pretax Margin | 24.37% |
| Profit Margin | 19.77% |
| EBITDA Margin | 30.45% |
| EBIT Margin | 25.68% |
| FCF Margin | 21.37% |
Dividends & Yields
This stock pays an annual dividend of $1.92, which amounts to a dividend yield of 1.05%.
| Dividend Per Share | $1.92 |
| Dividend Yield | 1.05% |
| Dividend Growth (YoY) | 8.05% |
| Years of Dividend Growth | 12 |
| Payout Ratio | 31.74% |
| Buyback Yield | -0.09% |
| Shareholder Yield | 0.95% |
| Earnings Yield | 3.29% |
| FCF Yield | 3.56% |
Analyst Forecast
The average price target for ResMed is $208.70, which is 13.56% higher than the current price. The consensus rating is "Buy".
| Price Target | $208.70 |
| Price Target Difference | 13.56% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 8.02% |
| EPS Growth Forecast (5Y) | 13.00% |
Stock Splits
The last stock split was on August 31, 2010. It was a forward split with a ratio of 2:1.
| Last Split Date | Aug 31, 2010 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
ResMed has an Altman Z-Score of 9.1 and a Piotroski F-Score of 5.
| Altman Z-Score | 9.1 |
| Piotroski F-Score | 5 |